PANG.MC Pangaea Oncology S.A.

Healthcare Biotechnology Madrid Exchange
1.47 EUR
Close of Oct 26, 2026
1.43 1.75
Market cap
EUR 52.8M
P/E
-
P/B
2.48x
ROE
-16.9%
Dividend yield
-
Fundamental score
1.4/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is PANG.MC undervalued?

Graham number

The Graham number of Pangaea Oncology S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pangaea Oncology S.A. fundamental analysis

6 of 21 checks passed

ROE 0/2

Low return on equity (-16.9%), below 10%.

ROA 0/1

Return on assets (-11.2%) is below the industry median (-1.9%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-174.8%) is below the industry median (41.0%).

Revenue Growth 2/2

Revenue grew 49.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (27.3%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Cash Runway 1/2

Cash covers 1.0 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (2.5x) is above the industry median (2.0x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Pangaea Oncology S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pangaea Oncology S.A.

Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatelli…

Full company profile